Background: Treatment with an immune checkpoint inhibitor (ICI) on completion of concurrent chemoradiotherapy (CCRT) for pts with inoperable stage III NSCLC significantly prolongs the PFS; however the best chemotherapy regimen in CCRT has not been established. This study was conducted to evaluate whether SP or DP, both with concurrent thoracic radiotherapy, in pts with inoperable stage III NSCLC showed a favorable 2-year OS rate with less toxicity in the SP arm as presented previously (J Clin Oncol 2017; 35, suppl; abstr 8534). An update of survival, relapsed sites and post-treatment information with prolonged follow-up has been awaited. Methods: Pts with inoperable stage III NSCLC were randomized to SP (S-1 40 mg/m
Background: Treatment with an immune checkpoint inhibitor (ICI) on completion of concurrent chemoradiotherapy (CCRT) for pts with inoperable stage III NSCLC significantly prolongs the PFS; however the best chemotherapy regimen in CCRT has not been established. This study was conducted to evaluate whether SP or DP, both with concurrent thoracic radiotherapy, in pts with inoperable stage III NSCLC showed a favorable 2-year OS rate with less toxicity in the SP arm as presented previously (J Clin Oncol 2017; 35, suppl; abstr 8534 ). An update of survival, relapsed sites and post-treatment information with prolonged follow-up has been awaited. Methods: Pts with inoperable stage III NSCLC were randomized to SP (S-1 40 mg/m 2 bid on days 1-14 and 29-42 plus cisplatin 60 mg/m 2 on days 1 and 29) or DP (docetaxel 50 mg/m 2 and cisplatin 80 mg/m 2 on days 1 and 29), with concurrent radiotherapy beginning on day 1 (60 Gy/30 fr) followed by two additional cycles of the chemotherapy. Primary endpoint was 2-year OS rate, and secondary endpoints included OS, PFS and safety. Results: Among 110 pts enrolled, 106 (53 in each arm) were evaluable, with male/ female 83/23; median age 65 (range 42-74); performance status 0/1 59/47; IIIA/IIIB 59/ 47. With a median follow-up of 48.1 months, 2-year survival and median OS were 79% (95% CI: 68-90%) and 55.2 months in the SP and 69% (95% CI: 57-82%) and 50.8 months in the DP arm, respectively. 5-year PFS rates in SP and DP arms were 23.2 (95% CI: 11-35) and 23.6% (95% CI: 11-36), and 5-year OS rates were 48.8 (95% CI: 34-64) and 42.3% (95%CI: 24-61), respectively. Hematological and non-hematological toxicities were less in the SP arm. Relapsed site in the RT field and in the CNS were similar between the two arms. Post-treatment chemotherapy for pts with progression was delivered in 92.5% and 71.1% pts in SP and DP arms, respectively. Conclusions: Because of favorable 2-year OS with less toxicity, we choose SP in CCRT as a future reference regimen. High 5-year PFS and OS rates shown here should be considered in designing further studies where CCRT is followed by ICI. Clinical trial identification: UMIN000005993. Legal entity responsible for the study: NPO Thoracic Oncology Research Group (TORG). Clinical-Biochemistry, Aarhus University Hospital, Aarhus, Denmark, 10 Medical Scientific Affairs, Roche Sequencing Solutions, Inc., Pleasanton, CA, USA Background: Only 20% of patients with locally advanced non-small cell lung cancer (NSCLC) have long term benefit from chemoradiation treatment. Analysis of ctDNA may be superior to other conventional approaches (e.g. CT imaging) in early detection of recurrent disease and can facilitate personalization of treatment strategies. Here we evaluate association between ctDNA levels and survival in subjects with locally advanced NSCLC using an ultra-sensitive next-generation sequencing (NGS) assay.
Methods: Treatment naive tumor and longitudinally collected plasma specimens were analyzed using a 197-gene NGS assay (AVENIO ctDNA Surveillance Kit and AVENIO Tumor Tissue Surveillance Kit prototype, Research Use Only). Mutations detected in pre-chemotherapy tumor specimens and in pre-chemotherapy or pre-radiation therapy plasma specimens were monitored in post-treatment plasma samples by measuring the number of Mutant Molecules Per Milliliter-of-plasma (MMPM). MMPM values were correlated with disease control (as evaluated by RECIST1.1). Kaplan-Meier curves and Cox proportional hazards models were used to assess association of tumor burden with subject survival. Results: We sequenced 36 tumor and 160 plasma specimens from 40 subjects. At least one mutation reporter was identified in 92% (n ¼ 27/33) of tumor and in 100% (n ¼ 31/31) of pre-chemo or 100% (n ¼ 37/37) of pre-radiation plasma specimens. The best predictive performance of the assay was observed using tumor pre-treatment reporters and MMPM cutoff of 8 in plasma samples collected at completion of the scheduled chemoradiation regimen. Subjects with MMPM below the cutoff had a mean overall survival (OS) benefit of 18.5 months (n ¼ 27, Tarone p-value¼0.013, HR ¼ 3.73, 95%CI ¼ 1.37-10.12). A similar trend was observed using plasma prechemo reporters (n ¼ 31, Tarone p-value¼0.024, HR ¼ 2.08, 95%CI ¼ 0.91-4.74). Conclusions: Circulating tumor DNA monitoring with an ultra-sensitive NGS-based assay identifies subjects with a locally advanced NSCLC who will have a more favorable outcome when treated with a stand-of-care chemoradiation therapy. Legal entity responsible for the study: Roche. Background: The main manifestations of radiation pneumonitis are injury of alveolar epithelial and endothelial cells, abnormal expression of cytokines, abnormal proliferation of fibroblasts and synthesis of fibrous matrix. The occurrence of radiation pneumonitis is associated with multiplecytokine level abnormality. These cytokines can also be used as bio-markers to predict the occurrence of radiation pneumonitis. Methods: NSCLC patients (68 cases) were treated with concurrent radiotherapy and chemotherapy, every patient's normal tissue were controlled with a same radation dose. 68 local advanced NSCLC patients with concurrent chemoradiotherapy were detected the levels of Ape1/Ref-1, ICAM-1 and IL-17A in serum by ELISA before radiotherapy and in the 14th week after radiotherapy. Acute and advanced radiation pulmonary injury was graded according to RTOG/EORTC diagnostic and grading criteria. Grade 2 or more radiation pneumonitis was taken as the main end point.
Results: Eighteen cases out of 68 developed radiation pneumonitis, 50 of 68 cases have no radiation pneumonia development. There was no significant change of Ape1/Ref-1 levels before and after radiotherapy in radiation pneumonitis group (P > 0.05). There was no significant change of Ape1/Ref-1 concentration in serum after radiotherapy between radiation pneumonitis group and non-radiation pneumonitis group (P > 0.05). Compared with before radiotherapy, upregulation degree of ICAM-1 levels in radiation pneumonitis group was higher than that in non-radiation pneumonitis group (P < 0.05). There was no significant change of IL-17A concentration before and after radiotherapy in radiation pneumonitis group, but after radiotherapy IL-17A concentration in serum were higher than that in non-radiation pneumonitis group (P < 0.05). Correlation analysis found that the change of ICAM-1 before and after radiotherapy has no obvious correlation with the incidence of radiation pneumonitis, and IL-17A change has obvious correlation with the incidence of radiation pneumonitis.
Conclusions: IL-17A in serum could be the predictive factors of radiation pneumonitis for local advanced NSCLC patients with concurrent chemoradiotherapy. Legal entity responsible for the study: Department of radiotherapy, affiliated Cancer Hospital, Zhengzhou University. 
